207 related articles for article (PubMed ID: 29266174)
1. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
Reardon DA; Lassman AB; Schiff D; Yunus SA; Gerstner ER; Cloughesy TF; Lee EQ; Gaffey SC; Barrs J; Bruno J; Muzikansky A; Duda DG; Jain RK; Wen PY
Cancer; 2018 Apr; 124(7):1438-1448. PubMed ID: 29266174
[TBL] [Abstract][Full Text] [Related]
2. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Lee EQ; Zhang P; Wen PY; Gerstner ER; Reardon DA; Aldape KD; deGroot JF; Pan E; Raizer JJ; Kim LJ; Chmura SJ; Robins HI; Connelly JM; Battiste JD; Villano JL; Wagle N; Merrell RT; Wendland MM; Mehta MP
Cancer; 2020 Jun; 126(12):2821-2828. PubMed ID: 32154928
[TBL] [Abstract][Full Text] [Related]
3. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Diéras V; Wildiers H; Jassem J; Dirix LY; Guastalla JP; Bono P; Hurvitz SA; Gonçalves A; Romieu G; Limentani SA; Jerusalem G; Lakshmaiah KC; Roché H; Sánchez-Rovira P; Pienkowski T; Seguí Palmer MÁ; Li A; Sun YN; Pickett CA; Slamon DJ
Breast; 2015 Jun; 24(3):182-90. PubMed ID: 25747197
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Monk BJ; Poveda A; Vergote I; Raspagliesi F; Fujiwara K; Bae DS; Oaknin A; Ray-Coquard I; Provencher DM; Karlan BY; Lhommé C; Richardson G; Rincón DG; Coleman RL; Herzog TJ; Marth C; Brize A; Fabbro M; Redondo A; Bamias A; Tassoudji M; Navale L; Warner DJ; Oza AM
Lancet Oncol; 2014 Jul; 15(8):799-808. PubMed ID: 24950985
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA
Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490
[TBL] [Abstract][Full Text] [Related]
6. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
Monk BJ; Poveda A; Vergote I; Raspagliesi F; Fujiwara K; Bae DS; Oaknin A; Ray-Coquard I; Provencher DM; Karlan BY; Lhommé C; Richardson G; Rincón DG; Coleman RL; Marth C; Brize A; Fabbro M; Redondo A; Bamias A; Ma H; Vogl FD; Bach BA; Oza AM
Gynecol Oncol; 2016 Oct; 143(1):27-34. PubMed ID: 27546885
[TBL] [Abstract][Full Text] [Related]
7. Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.
Kaufman PA; Wildiers H; Freyer G; Kemeny M; Gonçalves A; Jerusalem G; Stopeck A; Vrindavanam N; Dalenc F; Nanayakkara N; Wu B; Pickett CA
Clin Breast Cancer; 2019 Feb; 19(1):47-57. PubMed ID: 30420181
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
Sinkó D; Nemeskéri C
Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
Galanis E; Anderson SK; Lafky JM; Uhm JH; Giannini C; Kumar SK; Kimlinger TK; Northfelt DW; Flynn PJ; Jaeckle KA; Kaufmann TJ; Buckner JC
Clin Cancer Res; 2013 Sep; 19(17):4816-23. PubMed ID: 23833308
[TBL] [Abstract][Full Text] [Related]
10. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
Hong DS; Kurzrock R; Mulay M; Rasmussen E; Wu BM; Bass MB; Zhong ZD; Friberg G; Rosen LS
Oncotarget; 2014 Nov; 5(22):11154-67. PubMed ID: 25525888
[TBL] [Abstract][Full Text] [Related]
11. Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study.
Mooi J; Chionh F; Savas P; Da Gama Duarte J; Chong G; Brown S; Wong R; Price TJ; Wann A; Skrinos E; Mariadason JM; Tebbutt NC
Clin Cancer Res; 2021 Apr; 27(8):2159-2167. PubMed ID: 33514526
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
13. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
15. Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report.
D'Alessandris QG; Montano N; Martini M; Cenci T; Lauretti L; Stumpo V; Pignotti F; Olivi A; Fernandez E; Larocca LM; Pallini R
Acta Neurochir (Wien); 2018 Dec; 160(12):2387-2391. PubMed ID: 30306271
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Hainsworth JD; Becker KP; Mekhail T; Chowdhary SA; Eakle JF; Wright D; Langdon RM; Yost KJ; Padula GDA; West-Osterfield K; Scarberry M; Shaifer CA; Shastry M; Burris HA; Shih K
J Neurooncol; 2019 Sep; 144(2):303-311. PubMed ID: 31392595
[TBL] [Abstract][Full Text] [Related]
18. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E
Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379
[TBL] [Abstract][Full Text] [Related]
19. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
Schiff D; Jaeckle KA; Anderson SK; Galanis E; Giannini C; Buckner JC; Stella P; Flynn PJ; Erickson BJ; Schwerkoske JF; Kaluza V; Twohy E; Dancey J; Wright J; Sarkaria JN
Cancer; 2018 Apr; 124(7):1455-1463. PubMed ID: 29313954
[TBL] [Abstract][Full Text] [Related]
20. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Hong DS; Gordon MS; Samlowski WE; Kurzrock R; Tannir N; Friedland D; Mendelson DS; Vogelzang NJ; Rasmussen E; Wu BM; Bass MB; Zhong ZD; Friberg G; Appleman LJ
Clin Genitourin Cancer; 2014 Jun; 12(3):167-177.e2. PubMed ID: 24365125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
